Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold

The FDA has put a phase 1 trial of Cellectis’ off-the-shelf CAR-T therapy UCARTCS1A on clinical hold after learning of a death in the study. Cellectis said the multiple myeloma patient suffered a cardiac arrest after receiving the highest dose of the anti-CS1 allogeneic CAR-T.